The Wall Street Journal (12/5, Sebastian, Subscription Publication) reports Sage Therapeutics’ Sage-217 failed to meet its primary endpoint in a phase 3 trial testing the drug as a treatment for major depressive disorder. STAT (12/5, Robbins, Herper) reports the drug “did not show a statistically significant, anti-depressive benefit compared with a placebo.” (SOURCE: APA Headlines)